532nm激光联合复方樟柳碱治疗视网膜分支静脉阻塞的疗效  

Curative effect of 532nm laser combined with compound anisodine in treatment of branch retinal vein occlusion

作　　者：于清胜[1] 林丽霞[1] 牛英[1] 何菊花[1] 范扬[1] 齐玉彩[1] 

机构地区：[1]解放军第十医院五官科,中国甘肃省武威市733000

出　　处：《国际眼科杂志》2012年第12期2411-2412,共2页International Eye Science

摘　　要：目的:探讨倍频Nd:YAG 532nm激光联合复方樟柳碱治疗视网膜分支静脉阻塞(branch retinal vein occlusion,BRVO)的疗效。方法:选择130例130眼BRVO患者随机分为对照组和治疗组。对照组单纯应用532nm激光进行视网膜激光光凝治疗;治疗组在应用532nm激光进行视网膜激光光凝同时,加用复方樟柳碱局部封闭治疗。观察治疗3mo后两组患者视力变化情况,眼底荧光血管造影(fundus fluorescein angiography,FFA)检查视网膜循环情况。结果:联合复方樟柳碱治疗组与单纯激光治疗对照组相比,视力提高显著,差异有统计学意义(P=0.02<0.05)。直接检眼镜及FFA检查视网膜出血吸收、黄斑水肿减轻程度、毛细血管无灌注区消失、无新生血管形成等,治疗组均较对照组明显好转。结论:倍频Nd:YAG532nm激光联合复方樟柳碱治疗BRVO3mo后,视力及FFA检查明显优于单纯532nm激光治疗。AIM： To investigate the curative effect of Nd：YAG 532nm laser combined with compound anisodine in treatment of branch retinal vein occlusion （BRVO）.METHODS： Totally 130 cases 130 eyes of BRVO were randomly divided into control group and treatment group. The control group was treated by 532nm laser retinal laser photocoagulation, treatment group was treated by 532nm laser retinal photocoagulation combined with compound anisodine with local blocking. Observation of 3 months after treatment in two groups of patients with visual function and the changes of fundus fluorescein angiography （FFA） examination of retinal circulation.RESULTS： Combined compound anisodine treatment group compared with simple laser treatment control group, the difference was statistically significant in improved visual acuity （P=0.020.05）. Direct ophthalmoscopy and FFA examination revealed that the retinal hemorrhage absorption, the degree of macular edema reduction, capillary nonperfusion area disappearance, and no new blood vessel formation in the treatment group were better than those in control group.CONCLUSION： Double frequency Nd：YAG 532nm laser combined with compound anisodine in treatment of BRVO after 3 months, the visual function and FFA was significantly better than that of 532nm laser treatment.

关 键 词：视网膜分支静脉阻塞 激光光凝 复方樟柳碱 

分 类 号：R779.63[医药卫生—眼科]